808118-40-3

Solubility:Soluble in distilled water

Storage:-20C 2 years

Biologieal

SNS-032 (formerly BMS-387032) is a small-molecule cyclin-dependent kinase (CDK) inhibitor currently in phase I clinical trials for the treatment of B-cell malignancies and advanced solid tumors.Preclinical studies have shown that SNS-032 is a specific and potent inhibitor of CDK2, 7 and 9 which induces cell cycle arrest and apoptosis in tumor cell lines. It was shown to inhibit in vitro angiogenesis and prostaglandin E2 (PGE2) production, both strongly associated with tumorigenesis. Phase I clinical trials support the safety and tolerability of SNS-032 as evaluated in dose-escalation studies. The compound is currently administered by i.v. infusion but has shown promising potential for oral delivery.
 

Reference

1. Misra RN, et al. J Med Chem. 2004 Mar 25;47(7):1719-28.

2.Ali MA, et al. Neoplasia. 2007 May;9(5):370-81.

3.Heath EI, et al. Invest New Drugs. 2008 Feb;26(1):59-65. Epub 2007 Oct 16.